LudimilaCavalcanteMD

PubMed

• Pancreatic ductal adenocarcinoma: exploring clinicopathological trends and racial disparities in a comprehensive U.S. population-based study.
  Abdul Qahar Khan Yasinzai, Bisma Tareen, Katharine Tracy, Nimra Jamil, Marjan Khan, Hafeez Ullah, Muhammad Raza, Amin Ullah Khan, Dauod Arif, Abdul Waheed, Feroze Sidh...> ;Clinical & Translational Oncology. 2024 Apr 14
• Who Should Receive Immunotherapy for Advanced Gastroesophageal Cancer?
  Suhaib Khateeb, Ludimila Cavalcante, Noor Alnairat, Meghana Singh, Ibrahim Halil Sahin, Azhar Saeed, Anwaar Saeed> ;Current Treatment Options in Oncology. 2024 Apr 1
• Efficacy and safety of temozolomide-based regimens in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis.
  Erfan Taherifard, Muhammad Bakhtiar, Mahnoor Mahnoor, Rabeea Ahmed, Ludimila Cavalcante, Janie Zhang, Anwaar Saeed> ;BMC Cancer. 2024 Feb 12
• Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.
  Davis, E., Benedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, Anwaar Saeed, Howard Safran, Wen Wee Ma, Andrew L Coveler, Steven Powell, Bruno Bastos, Eli...> ;Clinical Cancer Research. 2024 Feb 1
• 1 citations
  Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches.
  Alireza Tojjari, Anwaar Saeed, Arezoo Sadeghipour, Razelle Kurzrock, Ludimila Cavalcante> ;Cancers. 2023 Nov 13
• Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patien...
  Choucair, K., Nebhan, C., Cortellini, A., Hentzen, S., Wang, Y., Liu, C., Giusti, R., Filetti, M., Ascierto, P., Vanella, V., Galetta, D., Catino, A., Al-Bzour, N., Sa...> ;Cancers. 2023 Oct 19
• SLAM Modification as an Immune-Modulatory Therapeutic Approach in Cancer.
  Alireza Tojjari, Francis J Giles, Maysa Vilbert, Anwaar Saeed, Ludimila Cavalcante> ;Cancers. 2023 Sep 29
• 1 citations
  Opposing Roles ofMutations in Human Prostate and Endometrial Cancers.
  Ludimila Cavalcante, Sachin Kumar Deshmukh, Jennifer R Ribeiro, Benedito A Carneiro, Don S Dizon, Kartik Angara, Tyler Mattox, Sharon Wu, Joanne Xiu, Phillip Walker, M...> ;JCO Precision Oncology. 2023 Sep 1
• 7 citations
  A Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma.
  Alireza Tojjari, Ahmed Saeed, Ludimila Cavalcante, Ibrahim Halil Sahin, Anwaar Saeed, Meghana Singh> ;Vaccines. 2023 Aug 12
• Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era.
  Hassan Abushukair, Stijn Hentzen, Ludimila Cavalcante, Anwaar Saeed, Radford, M.> ;Journal of Immunotherapy and Precision Oncology. 2023 Aug 1
• 2 citations
  Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis.
  Jonathan N Priantti, Maysa Vilbert, Thiago Madeira, Francisco Cezar A Moraes, Erica C Koch Hein, Anwaar Saeed, Ludimila Cavalcante> ;Cancers. 2023 Jul 25
• 4 citations
  Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma.
  Andrew Hsu, Kelsey E Huntington, Andre De Souza, Lanlan Zhou, Adam J Olszewski, Nirav P Makwana, Diana O Treaba, Ludimila Cavalcante, Francis J Giles, Howard Safran, W...> ;Cancer Biology & Therapy. 2022 Dec 31
• 3 citations
  Tumor Molecular and Microenvironment Characteristics in EBV-Associated Malignancies as Potential Therapeutic Targets: Focus on Gastric Cancer.
  Aviva Atri-Schuller, Hassan Abushukair, Ludimila Cavalcante, Stijn Hentzen, Azhar Saeed, Anwaar Saeed> ;Current Issues in Molecular Biology. 2022 Nov 18
• 12 citations
  Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3...
  Gary Shaw, Ludimila Cavalcante, Francis J Giles, Alison Taylor> ;Journal of Hematology & Oncology. 2022 Sep 14
• 2 citations
  Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies.
  Yazmin Odia, Ludimila Cavalcante, Howard Safran, Steven Francis Powell, Pamela N Munster, Wen Wee Ma, Benedito A Carneiro, Bruno R Bastos, Stacy Mikrut, William Mikrut...> ;Neuro-Oncology Advances. 2022 Feb 7
• 1 citations
  GSK3-beta as a candidate therapeutic target in soft tissue sarcomas.
  Stéphanie Verbeke, R. Perret, Vanessa Chaire, Elodie Richard, Valérie Velasco, F. Giles, L. Cavalcante, Antoine Italiano> ;Journal of Hematology & Oncology. 2021 Dec 2
• 10 citations
  GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties.
  Robin Park, Andrew L. Coveler, Ludimila Cavalcante, Anwaar Saeed> ;Biology. 2021 Jul 1
• 14 citations
  Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Mel...
  Ludimila Cavalcante, Akansha Chowdhary, Jeffrey A. Sosman, Sunandana Chandra> ;American Journal of Clinical Dermatology. 2018 Oct 1
• 22 citations
  Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease.
  Ludimila Cavalcante, Asim Amin, Jose Lutzky> ;Cancer Management and Research. 2015 Jan 19
• Frequent prosthesis refitting to prevent implant exposure in patients with retinoblastoma.
  Basil K Williams, Amy C. Schefler, Scott Garonzik, Daniel Gologorsky, Wei Shi, Ludimila L. Cavalcante, Milena L. Cavalcante, William J. Feuer, Timothy G. Murray> ;Journal of Pediatric Ophthalmology and Strabismus. 2011 Jul 1
• Join now to see all